Latin America Genomics

of Breast Cancer

Consortium

(LAGENO-BC)

Facilitating breast cancer genetic research through international collaboration

 

The Latin American Genomics of Breast Cancer Consortium (LAGENO-BC) is a collaborative effort including a multinational team of investigators sharing knowledge and materials to facilitate breast cancer genetics research relevant to the diverse populations of Latin America and its diaspora. LAGENO-BC aims to build a large research resource of genome wide genotype data including individuals from different countries and genetic ancestry proportions to study the Latin America-specific genetic architecture of breast cancer risk and survival.

International Collaboration

LAGENO-BC has members represent 12 different countries throughout Latin America. Find more information about the researchers that are a part of our consortium below.

Our Members
 

LAGENO-BC Data

LAGENO-BC has data on over 60,000 individuals throughout North and Latin America. Data includes basic demographics, reproductive variables, tumor characteristics, survival and treatment, and more. If you are interested in gaining access to LAGENO-BC data, please fill out our contact form

Data Access Inquiry
 

Studies Participating in LAGENO-BC

Our consortium has over 30 studies currently participating , find out more information below.

Studies
 

Similar Breast Cancer Consortia

LAGENO-BC is a part of the National Cancer Institute’s Confluence program, a large effort led by the NCI to discover genetic variations in breast cancer in diverse populations. You can learn more here (link)

 
 

  • The BCAC is a group of investigators interested in the inherited risk of breast cancer. The aim of the consortium is to combine data from many studies and to provide a reliable assessment of the risks associated with the gene.

  • The ABCC is a GWAS of Asian breast cancer cases and similar number of controls

  • The CIMBA was formed by a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA 1/2 mutation carriers. The aim of CIMBA is to provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers.

  • The MERGE is a GWAS of male breast cancer cases and similar number of controls.

 
 

Contact us

Feel free to contact us with any questions by filling out the contact form on the right.